Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPD489 in Preschool Children with ADHD
NCT03260205Phase 3Completed
- Sponsor
- Takeda
- Start
- Sep 2017
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of lisdexamfetamine in attention deficit hyperactivity disorder (ADHD), sponsored by Takeda. Started Sep 2017; status: completed.
02
Drugs
lisdexamfetamine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT03260205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03260205.